Stock Scorer

Ernexa Therapeutics Inc. (ERNA)

Ernexa Therapeutics Inc. reported revenue of 1K USD for the quarter ending 31 December 2024, down 94.1% from 17K a year earlier.

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than filled in. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. The same series drawn ›

As last reported

The newest period the filing supports for each figure, in USD.
FigurePeriodAmountYear on year
Revenue Q4 '24 · ending 31 December 2024 1K -94.1%
Gross Profit Q4 '24 · ending 31 December 2024 1K —
Operating Income Q2 '26 · ending 30 June 2026 -4.1M —
Net Income Q2 '26 · ending 30 June 2026 -4M —
Cost of Revenue Q2 '26 · ending 30 June 2026 0 -100.0%
Operating Cash Flow Q2 '26 · ending 30 June 2026 -4.2M —
Free Cash Flow Q2 '26 · ending 30 June 2026 -4.2M —
Shares Outstanding Q2 '26 · ending 30 June 2026 1.2M +733.1%
EPS Q3 '25 · ending 30 September 2025 -31.79 —

Revenue and profit by financial year

As filed, in USD. A year the filing does not support is not listed.
YearEnding RevenueOperating IncomeNet IncomeFree Cash Flow
20242024-12-31 582K-15.7M-44.5M-16.2M
20232023-12-31 68K-21.1M-21.7M-20.4M
20222022-12-31 0-33.2M-24.6M-21.3M
20202020-12-31 5.8M-7.2M-7.3M-8.1M
20192019-12-31 19.8M-1.8M-2M2.6M
20182018-12-31 23.3M203K-259K717K
20172017-12-31 21.3M-1.4M-1.1M-179K
20162016-12-31 22.3M-2.3M-2.9M-404K

Every period

Revenue Quarterly

PeriodEndingRevenue
Q4 '242024-12-311K
Q3 '242024-09-30487K
Q2 '242024-06-3047K
Q1 '242024-03-3147K
Q4 '232023-12-3117K
Q3 '232023-09-3051K
Q2 '232023-06-300
Q1 '232023-03-310
Q4 '222022-12-310
Q3 '222022-09-300
Q4 '202020-12-311.2M
Q3 '202020-09-301.5M
Q2 '202020-06-30754K
Q1 '202020-03-312.4M
Q4 '192019-12-315.2M
Q3 '192019-09-304.6M
Q2 '192019-06-305.2M
Q1 '192019-03-314.8M
Q4 '182018-12-315.9M
Q3 '182018-09-306M

Gross Profit Quarterly

PeriodEndingGross Profit
Q4 '242024-12-311K
Q3 '242024-09-30547K
Q2 '242024-06-30-48K
Q1 '242024-03-31-14K
Q4 '232023-12-31-49K
Q3 '232023-09-30-69K
Q2 '232023-06-300
Q1 '232023-03-31-50K
Q4 '222022-12-310
Q3 '222022-09-300

Operating Income Quarterly

PeriodEndingOperating Income
Q2 '262026-06-30-4.1M
Q1 '262026-03-31-5.6M
Q4 '252025-12-31-2.1M
Q3 '252025-09-30-2M
Q2 '252025-06-30-2.5M
Q1 '252025-03-31-2.7M
Q4 '242024-12-31-2.7M
Q3 '242024-09-30-2.3M
Q2 '242024-06-30-4.9M
Q1 '242024-03-31-5.8M
Q4 '232023-12-31-5.8M
Q3 '232023-09-30-5.5M
Q2 '232023-06-30-4.5M
Q1 '232023-03-31-5.3M
Q4 '222022-12-31-4.7M
Q3 '222022-09-30-8.3M
Q2 '222022-06-30-13.9M
Q1 '222022-03-31-6.3M
Q4 '212021-12-31-8.5M
Q3 '212021-09-30-86.3M

Net Income Quarterly

PeriodEndingNet Income
Q2 '262026-06-30-4M
Q1 '262026-03-31-5.5M
Q4 '252025-12-31-1.5M
Q3 '252025-09-30-1.2M
Q2 '252025-06-30-3.1M
Q1 '252025-03-31-8.2M
Q4 '242024-12-31-5.8M
Q3 '242024-09-30-26.6M
Q2 '242024-06-30-5.5M
Q1 '242024-03-31-6.6M
Q4 '232023-12-31-6.2M
Q3 '232023-09-30-5.6M
Q2 '232023-06-30-4.5M
Q1 '232023-03-31-5.4M
Q4 '222022-12-31-4.5M
Q3 '222022-09-30-7.3M
Q2 '222022-06-30-3.4M
Q1 '222022-03-31-9.4M
Q4 '212021-12-31-8M
Q3 '212021-09-30-86M

Cost of Revenue Quarterly

PeriodEndingCost of Revenue
Q2 '262026-06-300
Q2 '252025-06-300
Q4 '242024-12-310
Q3 '242024-09-30-60K
Q2 '242024-06-3095K
Q1 '242024-03-3161K
Q4 '232023-12-3166K
Q3 '232023-09-30120K
Q2 '232023-06-300
Q1 '232023-03-3150K
Q4 '222022-12-310
Q3 '222022-09-300

Operating Cash Flow Quarterly

PeriodEndingOperating Cash Flow
Q2 '262026-06-30-4.2M
Q1 '262026-03-31-2.3M
Q4 '252025-12-31-1.1M
Q3 '252025-09-30-1.3M
Q2 '252025-06-30-2.5M
Q1 '252025-03-31-2.1M
Q4 '242024-12-31-3.5M
Q3 '242024-09-30-6.3M
Q2 '242024-06-30-2.3M
Q1 '242024-03-31-3.7M
Q4 '232023-12-31-4.7M
Q3 '232023-09-30-5.8M
Q2 '232023-06-30-3.9M
Q1 '232023-03-31-6M
Q4 '222022-12-31-5.4M
Q3 '222022-09-30-6.1M
Q2 '222022-06-30-4M
Q1 '222022-03-31-5.4M
Q4 '212021-12-31-6.8M
Q3 '212021-09-30-6.4M

Free Cash Flow Quarterly

Operating cash flow minus capital expenditure.

PeriodEndingFree Cash Flow
Q2 '262026-06-30-4.2M
Q1 '262026-03-31-2.3M
Q4 '252025-12-31-1.2M
Q4 '242024-12-31-3.5M
Q3 '242024-09-30-6.3M
Q2 '242024-06-30-2.5M
Q1 '242024-03-31-3.8M
Q4 '232023-12-31-4.7M
Q3 '232023-09-30-5.8M
Q2 '232023-06-30-3.9M
Q1 '232023-03-31-6M
Q4 '222022-12-31-5.5M
Q3 '222022-09-30-6.2M
Q2 '222022-06-30-4.2M
Q1 '222022-03-31-5.5M
Q4 '212021-12-31-7M
Q3 '212021-09-30-6.4M
Q2 '212021-06-30-6.8M
Q1 '212021-03-31-3.4M
Q4 '202020-12-31-1.7M

Shares Outstanding Quarterly

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

PeriodEndingShares Outstanding
Q2 '262026-06-301.2M
Q1 '262026-03-31792K
Q3 '252025-09-308.2M
Q2 '252025-06-30207K
Q1 '252025-03-31142K
Q3 '242024-09-30361K
Q2 '242024-06-30361K
Q1 '242024-03-315.4M
Q3 '232023-09-305.4M
Q2 '232023-06-305.3M
Q1 '232023-03-315.1M
Q3 '222022-09-302.9M
Q2 '222022-06-302.9M
Q1 '222022-03-312.7M
Q3 '212021-09-302.5M
Q2 '212021-06-3042.4M
Q1 '212021-03-3127.8K
Q3 '202020-09-3017.6M
Q2 '202020-06-3017.6M
Q1 '202020-03-3117.5M

EPS TTM

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

PeriodEndingEPS
Q3 '252025-09-30-31.79
Q2 '252025-06-30-105.34
Q1 '252025-03-31-105.49
Q4 '242024-12-31-48.96
Q3 '242024-09-30-91.41
Q2 '242024-06-30-18.74
Q1 '242024-03-31-4.25
Q4 '232023-12-31-4.08
Q3 '232023-09-30-3.96
Q2 '232023-06-30-5.42
Q1 '232023-03-31-5.73
Q4 '222022-12-31-8.17
Q3 '222022-09-30-6.97
Q2 '222022-06-30-38.51
Q1 '222022-03-31-37.59
Q4 '202020-12-31-0.41
Q3 '202020-09-30-0.74
Q2 '202020-06-30-0.75
Q1 '202020-03-31-0.66
Q4 '192019-12-31-0.71